Direct comparison
503A vs 503B Compounding Pharmacy
503A traditional compounding vs 503B outsourcing facilities: cGMP, prescription requirements, FDA registration, and when you must use a 503B.
Ask about 503A vs 503B Compounding Pharmacy
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do 503A (traditional compounding), 503B (outsourcing facility) compare side by side?
The table below compares 503A (traditional compounding), 503B (outsourcing facility) across 11 procurement-relevant dimensions, from statutory basis through usp <795>/<797>/<800> compounding standards.
Side-by-side comparison
| Dimension | 503A (traditional compounding) | 503B (outsourcing facility) |
|---|---|---|
| Statutory basis | FD&C Act Section 503A, added by the FDA Modernization Act of 1997 | FD&C Act Section 503B, added by the Drug Quality and Security Act of 2013 |
| Typical operator | Retail and hospital pharmacies, physician offices | Dedicated outsourcing facilities (some are pharmacy-affiliated, some independent) |
| Patient-specific prescription required? | Generally yes — must be compounded pursuant to a valid, patient-specific prescription (with a narrow allowance for limited anticipatory compounding based on documented, established prescribing history) | No — this is the whole reason 503B exists: facilities may compound in anticipation of orders ("office stock") without a patient-specific prescription, as well as to patient-specific orders |
| FDA registration | Not required to register as a 503A compounder; oversight is primarily via state pharmacy licensure | Mandatory annual registration with FDA as an outsourcing facility, plus applicable facility fees |
| cGMP applies? | No — exempt from current good manufacturing practice requirements when operating within 503A conditions | Yes — must comply with cGMP, FDA's manufacturing-quality framework for drug products |
| Routine FDA inspection | Not routine — FDA oversight is limited; state boards of pharmacy are the primary regulator | Yes — subject to routine risk-based FDA inspections as a registered outsourcing facility |
| Adverse event reporting to FDA | No federal mandatory reporting requirement (state requirements vary) | Mandatory adverse event reporting to FDA |
| Primary regulator | State board of pharmacy | FDA (with state pharmacy licensure typically still applicable in parallel) |
| Bulk drug substances allowed | Must generally come from an FDA-approved source, meet a USP/NF monograph, or appear on the 503A bulk drug substances list | Must generally come from an FDA-approved source, meet a USP/NF monograph, or appear on the separate 503B bulk drug substances list (evaluated under its own nomination process) |
| Batch size / anticipatory compounding | Limited — anticipatory compounding without a prescription is restricted to "limited quantities" tied to documented, established prescribing patterns | Permitted at larger scale — 503B facilities are the pathway designed for producing standardized, ready-to-use compounded products ahead of specific orders |
| USP <795>/<797>/<800> compounding standards | Apply as the state-enforced compounding practice/quality standard (facility design, personnel, environmental monitoring, hazardous drug handling) | Also apply, and typically operate alongside — not instead of — the facility's cGMP program; the two regimes are complementary, not substitutes for one another |
Common questions
Common questions about 503A (traditional compounding) vs 503B (outsourcing facility)
When must a hospital or clinic use a 503B outsourcing facility instead of a 503A pharmacy?
+
When the product is needed without a patient-specific prescription — for example, stocking pre-filled syringes or IV bags ready for immediate use across multiple patients ("office stock") — a 503A pharmacy generally cannot supply that under its patient-specific prescription requirement. That is the core reason 503B exists: it is the legal pathway for anticipatory, non-patient-specific compounded supply at meaningful scale.
Is a 503B facility automatically "safer" than a 503A pharmacy?
+
Not automatically — 503B facilities are subject to cGMP and routine FDA inspection, which is a more rigorous federal quality framework than the state-board oversight that governs 503A pharmacies, but a 503A pharmacy following USP <795>/<797>/<800> correctly is also operating under an established quality standard. The two regimes address different risk profiles: 503B primarily addresses the risk of producing large batches for many patients without patient-specific orders; USP chapters address sterile/nonsterile/hazardous-drug compounding practice regardless of which FD&C pathway applies.
Do USP <795>, <797>, and <800> apply differently to 503A vs 503B?
+
The chapters themselves set the same compounding-practice standard either way (facility design, personnel training, environmental monitoring, hazardous drug handling, beyond-use dating). What differs is the FD&C legal pathway layered on top: a 503B facility must meet USP compounding standards and cGMP, while a 503A pharmacy must meet USP compounding standards under state board of pharmacy enforcement without a separate federal cGMP requirement.
Can the same organization operate both a 503A pharmacy and a 503B facility?
+
Yes — some organizations maintain a 503A compounding pharmacy for patient-specific orders alongside a separately registered 503B outsourcing facility for anticipatory/office-stock production, since the two serve different order types under different regulatory pathways.
